Introduction
============

*K. pneumoniae* is one of the most common pathogens in clinical infections, such as pneumonia, urinary tract infections, sepsis, wound infections, meningitis and other diseases. Multidrug-resistant *K. pneumoniae* strains are becoming a severe problem worldwide, and it usually carries one or more extended-spectrum β-lactamases (ESBLs) that confers the resistance to expanded-spectrum cephalosporins ([@b15-bjm-44-435]; [@b8-bjm-44-435]). In recent years, *K. pneumoniae* strains have been reported to be resistant to most β-lactamas through mutation genes encoded in chromosome, acquisition of genes from mobile plasmids and integrons ([@b16-bjm-44-435]; [@b18-bjm-44-435]).

Carbapenem antibiotics are very effective in the treatment of severe bacterial infections caused by ESBL- and AmpC enzymes-producing *K. pneumoniae* strains so that they have been widely used in clinics. Due to carbapenemases, metallo-β-lactamases and porin loss, carbapenem-resistant *K. pneumoniae* strains are increasing ([@b14-bjm-44-435]; [@b20-bjm-44-435]). Up to now, it has been reported that the outer membrane proteins of *K. pneumoniae* strains contain three known porins including OmpK35, OmpK36, and OmpK37 ([@b7-bjm-44-435]; [@b12-bjm-44-435]). Furthermore, porins OmpK35 and OmpK36 play critical roles in the penetration of antibiotics into the cells, and the loss of OmpK35 or OmpK36 can resist or reduce susceptibility to cephalosporins and carbapenems, particularly in strains containing Ambler group A, B, C, or D β-lactamase ([@b3-bjm-44-435]; [@b5-bjm-44-435]; [@b13-bjm-44-435]).

In 2010, we isolated 5 *K. pneumoniae* strains resistant to almost all antibiotics from clinical specimens. The minimal inhibitory concentrations (MICs) of piperacillin, piperacillin/tazobactam, amoxicillin/clavulanic acid, cefoperazone/sulbactam, cefoxitin, cefotaxime and aztreonam against 5 *K. pneumoniae* strains were larger than 128 μg/mL, and the MICs of imipenem and meropenem against 5 *K. pneumoniae* strains were larger than 32 μg/mL. In addition, these *K. pneumoniae* strains also revealed the resistance to ciprofloxacin, levofloxacin, gentamicin and amikacin (MIC ≥ 64 μg/mL). The objective of this study was to investigate the cause of high-level carbapenem resistance in *K. pneumoniae* strains. Except for *bla*TEM-1 and *bla*DHA-1 genes, carbapenem-resistant genes were not observed in 5 *K. pneumoniae* strains; however, the base deletion or mutation of *OmpK*35 and *OmpK*36 genes could lead to the alterations of amino acid sequences, protein configuration and pore size of porins, thus impeding the access of antimicrobials. Therefore, high-level resistance to cefoxitin and carbapenem in 5 *K. pneumoniae* clinical isolates is due to the combinatorial action from the production of blaDHA-1 beta-lactamase and the insertional inactivation or loss of porin OmpK36.

Methods
=======

Strains and antimicrobial susceptibility testing
------------------------------------------------

In 2010, 5 carbapenem-resistant *K. pneumoniae* (*Kp*01, *Kp*02, *Kp*03, *Kp*04 and *Kp*05) strains were isolated from sputum, urine and deep venous catheter specimens in a Chinese hospital. Among 5 patients, 1 case was from respiratory ward and 4 cases were from ICU ward. The MICs of piperacillin, peracillin/sulbactam, amoxicillin/clavulanic acid, cefoperazone/sulbactam, cefoxitin, cefotaxime, cefepime, aztreonam, imipenem, meropenem, ciprofloxacin, levofloxacin, gentamicin and amikacin were performed by E-test (Oxiod), and *E. coli ATCC25922* was used as the control.

Extraction of β-lactamase and three-dimensional test
----------------------------------------------------

Briefly, a colony was inoculated into 5 mL of tryptic soy broth overnight and the culture was grown at 35 °C for 4 h. The cells were concentrated by centrifugation, and crude enzyme extract was prepared by repeated freeze-thawing cycle for five times. The surface of a Mueller-Hinton agar plate was inoculated with *E.coli* strains as described by the standard disk diffusion method. A 30 μg cefoxitin disk (Oxoid) was placed on the inoculated agar. With a sterile scalpel blade, 4 slit beginning 5 mm from the edge of the disk was cut in the agar in outward radial direction. By using a pipette, 40 μL of crude enzyme extract was dispensed into each slit, beginning near the disk and moving outward. Slit overfill was avoided. The inoculated media were incubated overnight at 35 °C. Enhanced growth of the surface organism at the point where the slit intersected the zone of inhibition was considered a positive three-dimensional testing result and was interpreted as the evidence in the presence of AmpC beta-lactamase or ESBL. *K. pneumoniae* ATCC700603 and *Enterobacter cloacae* (*E. cloacae*) 029 M were used as the control strains.

Transconjugation experiments
----------------------------

In order to determine if the resistance was transferable, transconjugation experiments were performed. Five isolates were used as the donors and *E*C600 (Rif ^r^) was used as the recipient in transconjugation experiments. The organisms were inoculated into 5 mL of Luria-Bertani (LB) broth (Difco) and incubated at 35 °C for 20 h with shaking. Two organisms were mixed together at a proportion of 1 : 2, and then incubated overnight at 35 °C with shaking. After centrifugation for 5 min at 4,000 *g*, the precipitate was mixed with 1 mL of distilled water and inoculated onto MacConkey agar plates containing 600 μg/mL rifampin and 0.25 μg/mL cefotaxime. Transparent colonies were selected from the agar plates and inoculated into MacConkey agar again for activation. The drug-resistant profile and plasmid electrophoresis were further analyzed.

DNA extraction
--------------

Strains were grown overnight on MacConkey agar plates at 37 °C, and growth from approximately one-quarter of a plate was resuspended in 180 μL of distilled water. A total of 200 μL of buffer solution (0.01 mM Tris-HCl, pH 7.8; 0.005 M EDTA; 0.5% sodium dodecyl sulfate) and 20 μL of proteinase K (1 mg/mL) were added. The mixture was incubated at 55 °C for 2 h, and then 400 μL of phenol-chloroform solution was added, mixed with gentle agitation, and centrifuged at 12,000 *g* for 5 min. The supernatant was collected and DNA was precipitated after the addition of 0.5 volume of 7.5 M ammonium acetate and 2 volumes of ethanol. DNA was washed with 70% ethanol, dried, and resuspended with 100 μL of Tris-EDTA buffer.

Analysis of β-lactamase and porin genes
---------------------------------------

The oligonucleotide primers were designed on the basis of the nucleotide sequence in GenBank ([Table 1](#t1-bjm-44-435){ref-type="table"}). The 27 β-lactamase and 2 porin genes were screened by PCR. The primer pairs were shown in [Table 1](#t1-bjm-44-435){ref-type="table"}. The assay was carried out in 20 μL of reaction mixture containing 0.5 μM each primer, 10 mM KCl, 2 mM MgCl~2~, 8 mM (NH4)~2~SO~4~, 10 mM Tris-HCl (pH 9.0), 200 μM dNTP and 1 U Taq DNA polymerase. All amplification reactions were performed with an initial denaturation at 93 °C for 3 min followed by 35 cycles of denaturation at 93 °C for 1 min, annealing at 55 °C for 1 min and extension at 72 °C for 1 min. The final extension was performed at 72 °C for 7 min. Aliquot (20 μL) of each sample was subjected to electrophoresis by 2% agarose gels. The amplicons were purified with PCR Cleanup kits (Roche Molecular Biochemicals) and sequenced on an ABI PRISM 377 analyzer (Applied Biosystems).

Outer membrane protein analysis
-------------------------------

*K. pneumoniae* was inoculated overnight in 5 mL of LB medium at 35 °C with shaking, the culture was added in 200 mL of LB liquid medium at 35 °C with shaking for 5 h. After centrifugation (4 °C) for 5 min at 4,000 *g*, the supernatant was discarded. The precipitate was washed three times with 50 mM (pH 7.0) phosphate buffer solution (PBS), and suspended in 10 mM Tris-HCl (pH 7.4). The ultrasonic fragmentation of bacteria was performed in ice bath conditions. In order to remove unbroken bacteria, centrifugation was performed at 4,000 *g* for 30 min, and then the supernatant was centrifuged at 25,000 *g* for another 30 min. The precipitation was resuspended with buffer, and phenylmethylsulfonyl was added. The outer membrane protein was denatured at 100 °C for 5 min before electrophoresis and then separated by SDS-PAGE with Mini-sub cell horizontal electrophoresis tank (Biorad Co.). The gel concentration was 12.0%, and stained with Coomassie brilliant blue R250 for 30 min.

Inhibitory effects of reserpine and CCCP against efflux
-------------------------------------------------------

Susceptibility test was carried out using agar dilution method. MIC changes were observed in the absence or presence of reserpine (J & K Chemical) and CCCP (Sigma) at concentrations of 30 μg/mL and 50 μg/mL, respectively. An inoculum of each isolate at the amount of 5 × 10^4^ cfu/mL was inoculated onto MH medium containing serial dilutions of imipenem and meropenem. A phenotype for positive efflux was detectable after at least 4-fold dilutions of MIC for imipenem or meropenem in the absence or presence of reserpine and CCCP.

Results
=======

Antimicrobial susceptibility test
---------------------------------

*In vitro* tests showed that the MICs of piperacillin, piperacillin/tazobactam, amoxicillin/clavulanic acid, cefoperazone/sulbactam, cefoxitin, cefotaxime and aztreonam against 5 *K. pneumoniae* strains were larger than 128 μg/mL, and the MICs of imipenem or meropenem against 5 *K. pneumoniae* strains were larger than 32 μg/mL. In addition, 5 *K. pneumoniae* strains also revealed strong resistance to ciprofloxacin, levofloxacin, gentamicin and amikacin ([Table 2](#t2-bjm-44-435){ref-type="table"}).

Three dimension test
--------------------

All 5 isolates exhibited positive three-dimensional test results, and their extracts promoted the growth of one surface organism of *E.coli* ATCC25922 on MH agar. *E. cloacae* 029 M could produce AmpC enzyme to exhibit an interference with the growth of ATCC25922. ATCC700603 was used as the negative control ([Figure 1](#f1-bjm-44-435){ref-type="fig"}).

Sequence analysis of β-lactamase, *OmpK35* and *OmpK36* genes
-------------------------------------------------------------

The PCR and sequence analysis showed that *Kp*01, *Kp*02, *Kp*03, *Kp*04 and *Kp*05 contained TEM and DHA β-lactamase genes. Compared with *bla*TEM-1 (Accession No. FJ668746) and *bla*DHA-1 (Accession No. HM193083) in GenBank, these strains shared 100% identity. Similarly, *OmpK*35 and *OmpK*36 genes in 5 multidrug-resistant *K. pneumoniae* strains were detected by PCR amplification and sequence analysis. Among 5 *K. pneumoniae* strains, the base deletions of *OmpK35* and *OmpK36* genes were observed in *Kp*01 and *Kp*03 strains, and the base deletion of *OmpK35* gene was also observed in *Kp*02 and *Kp*05. In *OmpK*36 gene, insertion and deletion as well as the mutations of short DNA fragment (1--5 bp) could result in the alteration of open reading frame and early termination of translation. In addition, mutations of *OmpK35* gene occurred in *Kp*04 ([Table 3](#t3-bjm-44-435){ref-type="table"}). Compared with GU945384 in GenBank, *OmpK35* gene mutations of G → C at base 465 and T → C at base 466 in *Kp*04 could also result in the substitution from Gln to His at position 155 and substitution from Tyr to His at position 156. A new subtype has been registered in GenBank (Accession No. HQ259027).

Transconjugation test of *K. pneumoniae*
----------------------------------------

*EC*600 was used as the recipient in the conjugation studies. In addition, *bla*DHA-1 resistant genes from *Kp*01, *Kp*02, *Kp*03 and *Kp*05 were transferred into the recipient *EC*600 and confirmed by PCR. *EC*600 resulted in drug resistance from *Kp*01, *Kp*02, *Kp*03 and *Kp*05 to a certain degree, and the MICs of piperacillin, piperacillin/sulbactam, amoxicillin/clavulanic acid and cefotaxime exhibited 2--16 fold increase ([Table 4](#t4-bjm-44-435){ref-type="table"}).

SDS-PAGE of outer membrane protein
----------------------------------

The outer membrane proteins of 4 strains were detected by SDS-PAGE. Compared with the sensitive strains, the lack of outer membrane proteins in 3 carbepenem-resistant *K. pneumoniae* strains (*Kp*01, *Kp*02 and *Kp*04) were detected by SDS-PAGE, and molecular weights of these outer membrane proteins were 34--40 kDa, which suggested that only porin loss of OmpK36 in *Kp*01, *Kp*02 and *Kp*04 strains when compared with *K. pneumoniae* ATCC700603 and sensitive strains. In contrast, the porin of OmpK35 and OmpK36 was remained in *Kp*03 ([Figure 2](#f2-bjm-44-435){ref-type="fig"}).

Inhibitory effects of reserpine and CCCP on the efflux of *K. pneumoniae*
-------------------------------------------------------------------------

All strains with a concentration of 5 × 10^4^ cfu/mL can grow in the presence of 256 μg/mL reserpine and 128 μg/mL CCCP. When reserpine (30 μg/mL) and CCCP (50 μg/mL) were added in imipenem and meropenem, no change of MICs was observed in the presence of reserpine and CCCP.

Discussion
==========

In the present study, we screened 27 β-lactamase genes including Ambler class A, B, C and D by using PCR technique. The metallo-β-lactamases, OXA-type and KPC-type β-lactamases were not detected by PCR in 5 *K. pneumoniae* strains. However, all of 5 strains carried *bla*TEM-1 and *bla*DHA-1 β-lactamase genes. DHA-1, a plasmid-mediated AmpC type β-lactamase belonging to Ambler class C, can confer the resistance to oxyiminocephalosporins (cefotaxime and ceftazidime) and cephamycins (cefoxitin and moxalactam), and transfer of the resistance has been confirmed by transconjugation ([@b15-bjm-44-435]; [@b2-bjm-44-435]; [@b24-bjm-44-435]). In the present study, *bla*DHA-1 resistant genes from *Kp*01, *Kp*02, *Kp*03 and *Kp*05 may be transferred into the recipient *EC*600, leading to 2--16 fold MIC increase of piperacillin, piperacillin/sulbactam, amoxicillin/clavulanic acid and cefotaxime. These findings indicate that *bla*DHA-1 β-lactamase gene can spread rapidly between the same and different bacteria.

The base deletion of *OmpK*35 and *OmpK*36 genes in *Kp*01 and *Kp*03 was simultaneously observed. Similarly, the base deletion of *Omp*K35 also existed in *Kp*02 and *Kp*05. In addition, there were still genetic insertion of *Omp*K36 in *Kp*02, *Kp*04 and *Kp*05. SDS-PAGE analysis of the OMPs revealed the only loss of *Omp*K36 in *Kp*01, *Kp*02 and *Kp*04 strains when compared with *K. pneumoniae* ATCC700603 and a sensitive strains. However, the loss of porin was not observed in *Kp*03, which suggested that mutations or base deletions of porin-coding genes can lead to the alterations of open reading frame, amino acid sequences and protein configuration. Thus, the pore size of porin OmpK35 or OmpK36 can be affected and the accessibility of drugs can be impeded. Moreover, the porin OmpK36 plays an important role in the resistance or reduced susceptibility to carbapenems in *K. pneumoniae* strains ([@b7-bjm-44-435]; [@b23-bjm-44-435]). In this study, high-level carbapenem resistance in 5 *K. pneumoniae* strains was associated with the deletion or mutation of porin genes. The lack or deficiency of outer membrane protein can result in the change of permeability and reduction of cell accessibility for antibiotics or other drugs, which plays an important role in the main channels ([@b17-bjm-44-435]; [@b4-bjm-44-435]; [@b10-bjm-44-435]; [@b14-bjm-44-435]). Therefore, *bla*DHA-1 β-lactamases combined with the absence of outer membrane proteins may confer to the carbapenems and cefoxitin resistance in *K. pneumoniae* strains ([@b22-bjm-44-435]; [@b11-bjm-44-435]).

Efflux systems that contribute to antibiotic resistance have been described for a number of clinically important bacteria ([@b6-bjm-44-435]; [@b1-bjm-44-435]; [@b9-bjm-44-435]). The overexpression of multi-drug efflux pumps can lead to low-level multi-drug resistance ([@b6-bjm-44-435]; [@b19-bjm-44-435]). It has been reported that reserpine and CCCP were used as the pumps inhibitors ([@b21-bjm-44-435]). Reserpine is a well-established inhibitor of efflux pumps among Gram-positive microorganisms and non-fermenting Gram-negative microorganisms. CCCP can destroy the proton gradient of bacterial transcytoplasm membrane, causing transport proteins to lose energy supply and eventually leading to the increasing accumulation of drug concentration ([@b25-bjm-44-435]). In this study, when reserpine and CCCP were added, MIC changes of imipenem and meropenem were not observed. The results indicated that the resistance of *K. pneumoniae* strains to carbapenems seems to be irrelevant to efflux.

Taken all together, the expression of porin OmpK36 coupled with *bla*DHA-1 β-lactamase genes plays an important role in conferring resistance of *K. pneumoniae* strains to carbapenems and cefoxitin in our hospital. Our findings highlight the urgent need to develop the strategies for the prevention and control of infections. Limited application of antimicrobials, especially for fluoroquinolones and cephalosporins, may be the effective strategies.
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![Three-dimensional test for five strain isolates. (1A) Enhanced growth of *E.coli* ATCC25922 was observed near agar slits containing enzyme extracts of *Kp*01, *Kp*02 and *E. cloacae* 029 M. Except for ATCC700603, all of them were AmpC producers. (1B) *Kp*03, *Kp*04, *Kp*05 and *E. cloacae* 029 M could interfere with the growth of *E. coli* ATCC25922.](bjm-44-435-g001){#f1-bjm-44-435}

![SDS-PAGE of outer membrane proteins. M: Marker; S1: ATCC700603; S2: sensitive strain.](bjm-44-435-g002){#f2-bjm-44-435}

###### 

Primers used in this study.

  Target genes           Primer sequence (3′ → 5′)          Size (bp)   GenBank accession no. of reference
  ---------------------- ---------------------------------- ----------- ------------------------------------
  Class A β-lactamases                                                  
  TEM                    P1: AGGAAGAGTATGATTCAACA                       
                         P2: CTCGTCGTTTGGTATGGC             535 bp      X54604
  SHV                    P1: TGCGCAAGCTGCTGACCAGC                       
                         P2: TTAGCGTTGCCAGTGCTCGA           305 bp      AY326946
  CTX-M-1 group          P1: ATGGTTAAAAAATCACTGCGC                      
                         P2: TCCCGACGGCTTTCCGCCTT           833 bp      GU125714
  CTX-M-2 group          P1: ATGATGACTCAGAGCATTCG                       
                         P2: TCCCGACGGCTTTCCGCCTT           833 bp      AY750915
  CTX-M-8 group          P1: ATGATGAGACATCGCGTTAAGCGG                   
                         P2: TTAATAACCGTCGGTGACGATTTTCGCG   876 bp      AF189721
                                                                        
  CTX-M-9 group          P1: CGGCCTGTATTTCGCTGTTG                       
                         P2: TCCCGACGGCTTTCCGCCTT           793 bp      AB205197
  CTX-M-25 group         P1: ATGATGAGAAAAAGCGTAAGGCGGGCG                
                         P2: TCCCGACGGCTTTCCGCCTT           876 bp      AY157676
  PER                    P1: AGTCAGCGGCTTAGATA                          
                         P2: CGTATGAAAAGGACAATC             978 bp      AJ621265
  GES                    P1: ATGCGCTTCATTCACGCAC                        
                         P2: CTATTTGTCCGTGCTCAGG            846 bp      AY219651
  VEB                    P1: GCGGTAATTTAACCAGA                          
                         P2: GCCTATGAGCCAGTGTT              961 bp      AY536743
  CARB                   P1: AAAGCAGATCTTGTGACCTATTC                    
                         P2: TCAGCGCGACTGTGATGTATAAAC       588 bp      S46063
  KPC                    P1: ATGTCACTGTATCGCCGTCTA                      
                         P2: TTACTGCCCGTTGACGCCCAA          882 bp      GU086225
  LAP                    P1: ATGAAAAAGATCCGCCTTATTATAA                  
                         P2: TTACCAGTTCTTAATTACTGAATC       858 bp      EF026092
                                                                        
  Class B β-lactamases                                                  
  IMP                    P1: CGGCCGCAGGAGAGGCTTT                        
                         P2: AACCAGTTTTGCCTTACCAT           587 bp      AJ223604
  VIM                    P1: ATTCCGGTCGGAGAGGTCCG                       
                         P2: GAGCAAGTCTAGACCGCCCG           633 bp      AY509609
  SPM                    P1: CTGCTTGGATTCATGGGCGCG          784 bp      AY341249
                         P2: CCTTTTCCGCGACCTTGCTCG                      
  NDM                    P1: TCAGCGCAGCTTGTCGGCCA           813 bp      HQ738352
                         P2: ATGGAATTGCCCAATATTATGCA                    
                                                                        
  Class C β-lactamases                                                  
  LEN                    P1: ATGCGTTATATTCGCCTGTG           591 bp      AM850914
                         P2: GGCGCTCAGATGCTGCGC                         
  OKP                    P1: AAGCGCTTCCCGGCGACGTG           362 bp      AM051141
                         P2: TTAGCGTTGCCAGTGCTCGA                       
  DHA                    P1: AACTTTCACAGGTGTGCTGGGT         405 bp      AY585202
                         P2: CCGTACGCATACTGGCTTTGC                      
  ACT                    P1: TCGGTAAAGCCGATGTTGCGG          303 bp      EF508682
                         P2: CTTCCACTGCGGCTGCCAGTT                      
  MOX                    P1: GCTGCTCAAGGAGCACAGGAT          520 bp      EU515248
                         P2: CACATTGACATAGGTGTGGTG                      
  ACC                    P1: ACAGCCTCAGCAGCCGGTTA           345 bp      AJ133121
                         P2: TTCGCCGCAATCATCCCTAG                       
  FOX                    P1: AACATGGGGTATCAGGGAGAT          190 bp      AY034848
                         P2: CAAAGCGCGTAACCGGATTGG                      
                                                                        
  Class D β-lactamases                                                  
  OXA-1 group            P1: CTGTTGTTTGGGTTTCGCAAG          440 bp      GQ438248
                         P2: CTTGGCTTTTATGCTTGATG                       
  OXA-2 group            P1: CAGGCGCTGTTCGTGATGAGTT         233 bp      FJ855130
                         P2: GCCTTCTATCCAGTAATCGCC                      
  OXA-10 group           P1: GTCTTTCAAGTACGGCATTA           822 bp      AY509609
                         P2: GATTTTCTTAGCGGCAACTTA                      
                                                                        
  Porin                                                                 
  ompK35                 P1: ATGATGAAGCGCAATATTCTGGCAGTGG   684 bp      GU945384
                         P2: TCGGCTTTGTCGCCATTGCCGTCA                   
  ompK36                 P1: ATGAAAGTTAAAGTACTGTCCCTC       1076 bp     HM000057
                         P2: GCCGGTATCTCTACCGACGAC                      

###### 

MICs of β-lactams, fluoroquinolones and aminoglycosides against *K. pneumoniae* strains.

  Antimicrobial agents          MIC (μg/mL)                                       
  ----------------------------- ------------- -------- -------- -------- -------- ---------
  Piperacillin                  \> 256        \> 256   \> 256   \> 256   \> 256   1
  Piperacillin/sulbactam        \> 256        \> 256   \> 256   \> 256   \> 256   1
  Amoxicillin/clavulanic acid   \> 256        \> 256   \> 256   \> 256   \> 256   0.5
  Cefoxitin                     \> 256        \> 256   \> 256   \> 256   \> 256   4
  Cefotaxime                    \> 256        \> 256   \> 256   \> 256   \> 256   0.25
  Cefoperazone/sulbactam        \> 256        \> 256   \> 256   \> 256   \> 256   ≤ 0.125
  Cefepime                      128           128      \> 256   \> 256   128      ≤ 0.125
  Aztreonam                     \> 256        \> 256   \> 256   \> 256   \> 256   ≤ 0.125
  Imipenem                      \> 32         \> 32    \> 32    \> 32    \> 32    ≤ 0.125
  Meropenem                     \> 32         \> 32    \> 32    32       32       ≤ 0.125
  Ciprofloxacin                 \> 128        \> 128   \> 128   64       128      ≤ 0.125
  Levofloxacin                  \> 128        \> 128   \> 128   64       64       ≤ 0.125
  Gentamicin                    \> 128        \> 128   \> 128   \> 128   128      ≤ 0.125
  Amikacin                      \> 128        \> 128   \> 128   128      128      ≤ 0.125

*Kp*01, *Kp*02, *Kp*03, *Kp*04 and *Kp*05: carbapenem-resistant *K. pneumoniae* strains.

###### 

Expression of two porins in five *K. pneumoniae* strains.

  Strains   *bla*TEM-1   *bla*DHA-1   *Omp*K36 gene   *Omp*K35 gene
  --------- ------------ ------------ --------------- ---------------
  *Kp*01    \+           \+           Base deletion   Base deletion
  *Kp*02    \+           \+           Insertion       Base deletion
  *Kp*03    \+           \+           Base deletion   Base deletion
  *Kp*04    \+           \+           Insertion       Mutation
  *Kp*05    \+           \+           Insertion       Base deletion

###### 

The antimicrobial susceptibility of transconjugants.

  Antimicrobial agents          MIC (μg/mL)                       
  ----------------------------- ------------- --------- --------- ---------
  Piperacillin                  8             16        4         8
  Piperacillin/sulbactam        4             8         8         4
  Amoxicillin/clavulanic acid   4             8         4         4
  Cefotaxime                    0.5           1         0.5       1
  Cefoperazone/sulbactam        0.25          0.125     0.125     0.25
  Aztreonam                     0.25          0.25      0.25      0.5
  Cefepime                      ≤ 0.125       ≤ 0.125   ≤ 0.125   ≤ 0.125
  Imipenem                      ≤ 0.125       ≤ 0.125   ≤ 0.125   ≤ 0.125
  Meropenem                     ≤ 0.125       ≤ 0.125   ≤ 0.125   ≤ 0.125
  Ciprofloxacin                 ≤ 0.125       ≤ 0.125   ≤ 0.125   ≤ 0.125
  Amikacin                      0.25          ≤ 0.125   0.25      0.25

Transconjugants: Tr.
